Transapical aortic 'valve-in-valve' procedure for degenerated stented bioprosthesis

  • Ferrari E
  • 16


    Mendeley users who have this article in their library.
  • 18


    Citations of this article.


Standard surgical aortic valve replacement with a biological prosthesis remains the treatment of choice for low- and mid-risk elderly patients (traditionally >65 years of age) suffering from severe symptomatic aortic valve stenosis or insufficiency, and for young patients with formal contraindications to long-lasting anticoagulation. Unfortunately, despite the fact that several technical improvements have noticeably improved the resistance of pericardial and bovine bioprostheses to leaflet calcifications and ruptures, the risk of early valve failure with rapid degeneration still exists, especially for patients under haemodialysis and for patients

Author-supplied keywords

  • Degenerated aortic bioprosthesis
  • High-risk patients
  • Redo cardiac surgery
  • Transapical aortic valve implantation
  • Valve-in-valve procedure

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Enrico Ferrari

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free